ImExHS Full Year 2024 Earnings: AU$0.058 loss per share (vs AU$0.11 loss in FY 2023)

Simply Wall St

ImExHS (ASX:IME) Full Year 2024 Results

Key Financial Results

  • Revenue: AU$26.5m (up 33% from FY 2023).
  • Net loss: AU$2.63m (loss narrowed by 41% from FY 2023).
  • AU$0.058 loss per share (improved from AU$0.11 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

ASX:IME Revenue and Expenses Breakdown April 5th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

ImExHS Earnings Insights

The primary driver behind last 12 months revenue was the Radiology segment contributing a total revenue of AU$18.1m (68% of total revenue). Notably, cost of sales worth AU$15.5m amounted to 59% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to AU$8.39m (62% of total expenses). Explore how IME's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Healthcare Services industry in Australia.

Performance of the Australian Healthcare Services industry.

The company's shares are down 1.3% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for ImExHS that we have uncovered.

Valuation is complex, but we're here to simplify it.

Discover if ImExHS might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.